Recent Updates — SNGX

On September 17, 2026, Soligenix stockholders approved an amendment to increase authorized common shares from 75 million to 125 million and granted the Board discretion to effect a reverse split between 1-for-2 and 1-for-20 within one year. The company also elected five directors and ratified its auditor. Separately, on June 26, 2026, Soligenix filed a prospectus supplement to increase the maximum aggregate offering amount under its At Market Issuance Sales Agreement with Rodman & Renshaw LLC by $2,500,000, bringing the total available capacity to approximately $8.9 million after previously selling about $6.234 million. Soligenix operates in the biotechnology industry, focusing on developing immunotherapies and vaccines.

Soligenix, Inc. filed a prospectus supplement on June 26, 2026, to increase the maximum aggregate offering amount of common stock issuable under its At Market Issuance Sales Agreement with Rodman & Renshaw LLC by an additional $2,500,000. The company previously sold approximately $6,234,000 of shares of common stock under the own Sales Agreement. Soligenix, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for neglected and orphan diseases.

On June 10, 2026, Soligenix received a Nasdaq Bid Price Notice stating it is non-compliant with the $1.00 minimum bid price requirement; the company has until December 7, 2026, to regain compliance. On June 11, 2026, the Board terminated the HyBryte development program following a Phase 3 FLASH2 trial recommendation of futility, estimating wind-down costs of approximately $70,000. Consequently, Dr. Richard C. Straube ceased serving as Consulting Chief Medical Officer, with responsibilities transitioning to Medical Director Dr. Christopher Pullion. The company will continue evaluating strategic options and other pipeline programs, including dusquetide for Behçet’s Disease. Soligenix is a biotechnology company that develops therapeutic products for various diseases.